Oncotarget

Meta-Analysis:

Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis

Zhaojun Shen, Hui Luo, Saisai Li, Bo Sheng, Menghuang Zhao, Haiyan Zhu and Xueqiong Zhu _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:62400-62413. https://doi.org/10.18632/oncotarget.18253

Metrics: PDF 464 views  |   HTML 1372 views  |   ?  


Abstract

Zhaojun Shen1, Hui Luo1, Saisai Li1, Bo Sheng1, Menghuang Zhao1, Haiyan Zhu1 and Xueqiong Zhu1

1Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China

Correspondence to:

Xueqiong Zhu, email: zjwzzxq@163.com

Haiyan Zhu, email: zhuhaiyandoc@sina.com

Keywords: epithelial ovarian cancer, estrogen receptor, prognosis, meta-analysis

Received: March 24, 2017     Accepted: April 26, 2017     Published: May 29, 2017

ABSTRACT

Objective: Accumulated studies have investigated the prognostic significance of estrogen receptor expression in epithelial ovarian cancer, but results remain controversial. The aim of this study was to perform a meta-analysis to clarify the prognostic value of estrogen receptor expression in epithelial ovarian cancer.

Methods: A systematic search was performed in PUBMED, EMBASE, and COCHRANE databases to identify relevant studies up to December 2016. The pooled hazard rates (HR) with 95% confidence intervals (CIs) for overall survival and time to tumor progression were calculated and then weighted and pooled in this meta-analysis with a random-effect model.

Results: Thirty-five studies with a total of 5824 patients were included. In brief, the expression of estrogen receptor was associated with an improved overall survival (HR = 0.86, 95% CI = 0.76-0.97), whereas there was no significant difference between estrogen receptor and time to tumor progression among epithelial ovarian cancer patients. Subgroup analysis revealed that estrogen receptor expression was significantly correlated with overall survival in different subgroups, such as in unclassified epithelial ovarian cancer (HR= 0.80, 95% CI = 0.66-0.95), studies using immunohistochemistry detection method (HR= 0.85, 95% CI = 0.73-1.00), European population (HR= 0.75, 95% CI = 0.60-0.94) and estrogen receptor α subtype (HR= 0.78, 95% CI = 0.62-0.98).

Conclusions: Estrogen receptor, especially estrogen receptor α, was associated with an improved overall survival in epithelial ovarian cancer. Estrogen receptor expression may be a promising prognostic factor in epithelial ovarian cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18253